Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 758639, 10 pages
http://dx.doi.org/10.1155/2014/758639
Review Article

Role of Cytokines and Toll-Like Receptors in the Immunopathogenesis of Guillain-Barré Syndrome

1Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka 5650871, Japan
2Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India

Received 29 June 2014; Accepted 13 August 2014; Published 22 September 2014

Academic Editor: Nina Ivanovska

Copyright © 2014 Kishan Kumar Nyati and Kashi Nath Prasad. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. Griffin, C. Y. Li, T. W. Ho et al., “Pathology of the motor-sensory axonal guillain-barré syndrome,” Annals of Neurology, vol. 39, no. 1, pp. 17–28, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Kuwabara, K. Ogawara, S. Misawa et al., “Does Campylobacter jejuni infection elicit “demyelinating” Guillain-Barré syndrome,” Neurology, vol. 63, no. 3, pp. 529–533, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. F. J. Vriesendorp, “Insights into Campylobacter jejuni-induced Guillain-Barre syndrome from the Lewis rat model of experimental allergic neuritis,” Journal of Infectious Diseases, vol. 176, no. 6, pp. S164–S168, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Hughes, P. Atkinson, P. Coates, S. Hall, and S. Leibowitz, “Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome,” Muscle and Nerve, vol. 15, no. 5, pp. 568–575, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Brechenmacher, C. Vital, and C. Deminiere, “Guillain-Barre syndrome: an ultrastructural study of peripheral nerve in 65 patients,” Clinical Neuropathology, vol. 6, no. 1, pp. 19–24, 1987. View at Google Scholar · View at Scopus
  6. J. M. Vallat, M. J. Leboutet, M. O. Jauberteau, F. Tabaraud, P. Couratier, and F. Akani, “Widenings of the myelin lamellae in a typical Guillain-Barre syndrome,” Muscle and Nerve, vol. 17, no. 4, pp. 378–380, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Griffin, G. Stoll, C. Y. Li, W. Tyor, and D. R. Cornblath, “Macrophage responses in inflammatory demyelinating neuropathies,” Annals of Neurology, vol. 27, supplement 1, pp. S64–S68, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sawant-Mane, M. B. Clark, and C. L. Koski, “In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes,” Annals of Neurology, vol. 29, no. 4, pp. 397–404, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Sawant-Mane, A. Estep III, and C. L. Koski, “Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype,” Journal of Neuroimmunology, vol. 49, no. 1-2, pp. 145–152, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Birchem, F. A. Mithen, K. M. L'Empereur, and M. M. Wessels, “Ultrastructural effects of Guillain-Barre serum in cultures containing only rat Schwann cells and dorsal root ganglion neurons,” Brain Research, vol. 421, no. 1-2, pp. 173–185, 1987. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-P. Hartung, C. Schwenke, D. Bitter-Suermann, and K. V. Toyka, “Guillain-barré syndrome: activated complement components C3a and C5a in CSF,” Neurology, vol. 37, no. 6, pp. 1006–1009, 1987. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L. Koski, M. E. Sanders, P. T. Swoveland et al., “Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies,” Journal of Clinical Investigation, vol. 80, no. 5, pp. 1492–1497, 1987. View at Publisher · View at Google Scholar · View at Scopus
  13. E. E. Magira, M. Papaioakim, I. Nachamkin et al., “Differential distribution of HLA-DQβ/DRβ epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQβ epitopes associated with susceptibility to and protection from AIDP,” Journal of Immunology, vol. 170, no. 6, pp. 3074–3080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Akira, K. Takeda, and T. Kaisho, “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunology, vol. 2, no. 8, pp. 675–680, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. B. Kopp and R. Medzhitov, “The Toll-receptor family and control of innate immunity,” Current Opinion in Immunology, vol. 11, no. 1, pp. 13–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. R. P. Lisak, D. Skundric, B. Bealmear, and S. Ragheb, “The role of cytokines in Schwann cell damage, protection, and repair,” Journal of Infectious Diseases, vol. 176, no. 6, pp. S173–S179, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. K. K. Nyati, K. N. Prasad, A. Rizwan, A. Verma, and V. K. Paliwal, “TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barré syndrome,” Archives of Neurology, vol. 68, no. 4, pp. 445–452, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Press, G. Deretzi, L. P. Zou et al., “IL-10 and IFN-γ in Guillain-Barre syndrome,” Journal of Neuroimmunology, vol. 112, no. 1-2, pp. 129–138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. K. K. Nyati, K. N. Prasad, A. Rizwan, A. Verma, V. K. Paliwal, and S. Pradhan, “Lymphocyte transformation test detects a response to Campylobacter jejuni antigens in patients with Guillain-Barré syndrome,” Medical Microbiology and Immunology, vol. 199, no. 2, pp. 109–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. K. K. Nyati, K. N. Prasad, N. K. Kharwar et al., “Immunopathology and Th1/Th2 immune response of Campylobacter jejuni-induced paralysis resembling Guillain-Barré syndrome in chicken,” Medical Microbiology and Immunology, vol. 201, no. 2, pp. 177–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Zhu, E. Mix, and H. Link, “Cytokine production and the pathogenesis of experimental autoimmune neuritis and Gulllain-Barre syndrome,” Journal of Neuroimmunology, vol. 84, no. 1, pp. 40–52, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Kikly, L. Liu, S. Na, and J. D. Sedgwick, “The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation,” Current Opinion in Immunology, vol. 18, no. 6, pp. 670–675, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Langowski, X. Zhang, L. Wu et al., “IL-23 promotes tumour incidence and growth,” Nature, vol. 442, no. 7101, pp. 461–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Hu, T. Dehmel, J. Pirhonen, H.-P. Hartung, and B. C. Kieseier, “Interleukin 23 in acute inflammatory demyelination of the peripheral nerve,” Archives of Neurology, vol. 63, no. 6, pp. 858–864, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Chabaud, T. Aarvak, P. Garnero, J. B. Natvig, and P. Miossec, “Potential contribution of IL-17-producing Th1 cells to defective repair activity in joint inflammation: partial correction with Th2-promoting conditions,” Cytokine, vol. 13, no. 2, pp. 113–118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. L. E. Harrington, R. D. Hatton, P. R. Mangan et al., “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,” Nature Immunology, vol. 6, no. 11, pp. 1123–1132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. A. N. Mathur, H.-C. Chang, D. G. Zisoulis et al., “T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype,” Blood, vol. 108, no. 5, pp. 1595–1601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Zhang, Z.-Y. Zhang, and H. J. Schluesener, “Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects,” Journal of Immunology, vol. 183, no. 5, pp. 3081–3091, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. L. J. Chi, W. H. Xu, Z. W. Zhang, H. T. Huang, L. M. Zhang, and J. Zhou, “Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 15, no. 4, pp. 345–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Li, M. Yu, H. Li, H. Zhang, and Y. Jiang, “IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome,” Mediators of Inflammation, vol. 2012, Article ID 260473, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-L. Liang, W.-Z. Wang, S. Huang, X.-K. Wang, S. Zhang, and Y. Wu, “Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in GuillainBarré syndrome,” Immunopharmacology and Immunotoxicology, vol. 34, no. 6, pp. 1039–1046, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S.-H. Pelidou, L.-P. Zou, G. Deretzi, C. Oniding, E. Mix, and J. Zhu, “Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role,” Experimental Neurology, vol. 163, no. 1, pp. 165–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Shen and S. L. Gaffen, “Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy,” Cytokine, vol. 41, no. 2, pp. 92–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Zepp, L. Wu, and X. Li, “IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease,” Trends in Immunology, vol. 32, no. 5, pp. 232–239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Li, P. Zhao, X. Sun, Y. Che, and Y. Jiang, “Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome,” Mediators of Inflammation, vol. 2013, Article ID 639712, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. N. McNamee, J. C. Masterson, P. Jedlicka et al., “Interleukin 37 expression protects mice from colitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. 16711–16716, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Sakai, H. L. van Sweringen, R. M. Belizaire et al., “Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells,” Journal of Gastroenterology and Hepatology, vol. 27, no. 10, pp. 1609–1616, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Kebir, K. Kreymborg, I. Ifergan et al., “Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation,” Nature Medicine, vol. 13, no. 10, pp. 1173–1175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Akashi-Takamura and K. Miyake, “Toll-like receptors (TLRs) and immune disorders,” Journal of Infection and Chemotherapy, vol. 12, no. 5, pp. 233–240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Gries, L. Davies, Y. Liu et al., “Response of Toll-like receptors in experimental Guillain-Barré syndrome: a kinetic analysis,” Neuroscience Letters, vol. 518, no. 2, pp. 154–160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Kuijf, J. N. Samsom, W. van Rijs et al., “TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation,” The Journal of Immunology, vol. 185, no. 1, pp. 748–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Huizinga, W. van Rijs, J. J. Bajramovic et al., “Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-β and TNF-α,” The Journal of Immunology, vol. 191, no. 11, pp. 5636–5645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. B. C. Mercier, A. Cottalorda, C.-A. Coupet, J. Marvel, and N. Bonnefoy-Bérard, “TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal,” Journal of Immunology, vol. 182, no. 4, pp. 1860–1867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Y. Zhang and H. J. Schluesener, “Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis,” Neuroscience, vol. 159, no. 1, pp. 136–142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Laurà, A. Mazzeo, M. Aguennouz et al., “Immunolocalization and activation of nuclear factor-κB in the sciatic nerves of rats with experimental autoimmune neuritis,” Journal of Neuroimmunology, vol. 174, no. 1-2, pp. 32–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Z. Wang, Q. H. Liang, H. Ramkalawan et al., “Expression of toll-like receptors 2, 4 and 9 in patients with guillain-barré syndrome,” NeuroImmunoModulation, vol. 19, no. 1, pp. 60–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. R. R. Schumann and R. I. Tapping, “Genomic variants of TLR1—It takes (TLR-)two to tango,” European Journal of Immunology, vol. 37, no. 8, pp. 2059–2062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Müller, M. Stenner, K. Wacker, E. B. Ringelstein, W. F. Hickey, and R. Kiefer, “Contribution of resident endoneurial macrophages to the local cellular response in experimental autoimmune neuritis,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 5, pp. 499–507, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Beaino and E. Trifilieff, “Thiopalmitoylated peptides from the peripheral nervous system myelin P0 protein: synthesis, characterization, and neuritogenic properties,” Bioconjugate Chemistry, vol. 21, no. 8, pp. 1439–1447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Y.-N. Deng and W.-B. Zhou, “Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis,” NeuroImmunoModulation, vol. 14, no. 6, pp. 337–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Marta, Å. Andersson, M. Isaksson, O. Kämpe, and A. Lobell, “Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis,” European Journal of Immunology, vol. 38, no. 2, pp. 565–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Pepper, F. Dzierszinski, E. Wilson et al., “Plasmacytoid dendritic cells are activated by Toxoplasma gondii to present antigen and produce cytokines,” Journal of Immunology, vol. 180, no. 9, pp. 6229–6236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. C. L. Lancioni, Q. Li, J. J. Thomas et al., “Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4+ T cell activation via toll-like receptors 1 and 2,” Infection and Immunity, vol. 79, no. 2, pp. 663–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Geleijns, B. C. Jacobs, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, and P. A. van Doorn, “Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 132–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Koga, N. Yuki, K. Kashiwase, K. Tadokoro, T. Juji, and K. Hirata, “Guillain-Barre and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies,” Journal of Neuroimmunology, vol. 88, no. 1-2, pp. 62–66, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Geleijns, G. M. T. Schreuder, B. C. Jacobs et al., “HLA class II alleles are not a general susceptibility factor in Guillain-barré syndrome,” Neurology, vol. 64, no. 1, pp. 44–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. J. J. Ma, M. Nishimura, H. Mine et al., “HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome,” Neurology, vol. 51, no. 2, pp. 379–384, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. K. N. Prasad, K. K. Nyati, A. Verma, A. Rizwan, and V. K. Paliwal, “Tumor necrosis factor-α polymorphisms and expression in Guillain-Barré syndrome,” Human Immunology, vol. 71, no. 9, pp. 905–910, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. K.-M. Myhr, K. S. Vågnes, T. H. Marøy, J. H. Aarseth, H. I. Nyland, and C. A. Vedeler, “Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 139, no. 1-2, pp. 81–83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. N. C. Arbour, E. Lorenz, B. C. Schutte et al., “TLR4 mutations are associated with endotoxin hyporesponsiveness in humans,” Nature Genetics, vol. 25, no. 2, pp. 187–191, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Maeda, M. Akanuma, Y. Mitsuno et al., “Distinct mechanism of Helicobacter pylori -mediated NF-κ B activation between gastric cancer cells and monocytic cells,” Journal of Biological Chemistry, vol. 276, no. 48, pp. 44856–44864, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. F. L. Rock, G. Hardiman, J. C. Timans, R. A. Kastelein, and J. F. Bazan, “A family of human receptors structurally related to Drosophila Toll,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 588–593, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. E. A. Leadbetter, I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein, “Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors,” Nature, vol. 416, no. 6881, pp. 603–607, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. K. K. Nyati, K. N. Prasad, A. Verma et al., “Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-barré syndrome in Northern Indian population,” Journal of Neuroimmunology, vol. 218, no. 1-2, pp. 116–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. C. M. Caporale, F. Papola, M. A. Fioroni et al., “Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes,” Journal of Neuroimmunology, vol. 177, no. 1-2, pp. 112–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Geleijns, A. Roos, J. J. Houwing-Duistermaat et al., “Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome,” Journal of Immunology, vol. 177, no. 6, pp. 4211–4217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Sinha, K. N. Prasad, D. Jain, K. K. Nyati, S. Pradhan, and S. Agrawal, “Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome,” Acta Neurologica Scandinavica, vol. 122, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. N. M. van Sorge, W.-L. van Der Pol, M. D. Jansen et al., “Severity of Guillain-Barré syndrome is associated with Fcγ receptor III polymorphisms,” Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 157–164, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Uncini, F. Notturno, M. Pace, and C. M. Caporale, “Polymorphism of CD1 and SH2D2A genes in inflammatory neuropathies,” Journal of the Peripheral Nervous System, vol. 16, no. 1, pp. 48–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. J. P. Pandey and C. A. Vedeler, “Immunoglobulin KM genes in Guillain-Barré syndrome,” Neurogenetics, vol. 4, no. 3, pp. 147–149, 2003. View at Google Scholar · View at Scopus
  71. M. J. H. J. Dekker, E. L. T. van Den Akker, J. W. Koper et al., “Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome,” Journal of the Peripheral Nervous System, vol. 14, no. 2, pp. 75–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Sharshar, M.-C. Durand, J.-P. Lefaucheur et al., “MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome,” Neurology, vol. 59, no. 10, pp. 1649–1651, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Kuwabara, “Guillain-Barré syndrome: epidemiology, pathophysiology and management,” Drugs, vol. 64, no. 6, pp. 597–610, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Vucic, M. C. Kiernan, and D. R. Cornblath, “Guillain-Barré syndrome: an update,” Journal of Clinical Neuroscience, vol. 16, no. 6, pp. 733–741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. K. Sharief, D. A. Ingram, M. Swash, and E. J. Thompson, “I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome,” Neurology, vol. 52, no. 9, pp. 1833–1838, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. F. G. van der Meche and P. I. Schmitz, “A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group,” The New England Journal of Medicine, vol. 326, no. 17, pp. 1123–1129, 1992. View at Publisher · View at Google Scholar · View at Scopus
  77. C. A. Thornton and M. Ballow, “Safety of intravenous immunoglobulin,” Archives of Neurology, vol. 50, no. 2, pp. 135–136, 1993. View at Publisher · View at Google Scholar · View at Scopus
  78. C. A. Thornton and R. C. Griggs, “Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease,” Annals of Neurology, vol. 35, no. 3, pp. 260–268, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. J.-C. Raphaël, S. Chevret, C. Chastang, and M.-C. Jars-Guincestre, “Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome,” Annals of Neurology, vol. 41, no. 3, pp. 298–306, 1997. View at Publisher · View at Google Scholar · View at Scopus
  80. F. J. Vriesendorp, G. S. Dmytrenko, T. Dietrich, and C. L. Koski, “Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy,” Archives of Neurology, vol. 50, no. 12, pp. 1301–1303, 1993. View at Publisher · View at Google Scholar · View at Scopus
  81. R. A. Hughes, A. V. Swan, J.-C. Raphaël, D. Annane, R. van Koningsveld, and P. A. van Doorn, “Immunotherapy for Guillain-Barré syndrome: a systematic review,” Brain, vol. 130, no. 9, pp. 2245–2257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. R. A. Hughes, A. V. Swan, and P. A. van Doorn, “Intravenous immunoglobulin for Guillain-Barré syndrome,” Cochrane Database System Review, vol. 7, p. CD002063, 2012. View at Google Scholar · View at Scopus
  83. R. A. Hughes, J. M. Newsom-Davis, G. D. Perkin, and J. M. Pierce, “Controlled trial of prednisolone in acute polyneuropathy,” The Lancet, vol. 2, no. 8093, pp. 750–753, 1978. View at Google Scholar · View at Scopus
  84. N. K. Singh and A. Gupta, “Do corticosteriods influence the disease course or mortality in Guillain-Barre' syndrome?” The Journal of Association of Physicians of India, vol. 44, no. 1, pp. 22–24, 1996. View at Google Scholar · View at Scopus